Table 2 Comparison of clinicopathological factors between the NRF and RF groups
Variable | NRF group | RF group | p-value |
|---|---|---|---|
|  | (n = 152) | (n = 59) |  |
ESD history | Â | Â | 0.101 |
    +  | 26 (17.1) | 16 (27.1) |  |
    −  | 126 (82.9) | 43 (72.9) |  |
CRT history | Â | Â | 0.0233 |
    +  | 8 (5.3) | 9 (15.3) |  |
    −  | 144 (94.7) | 50 (84.7) |  |
Location | Â | Â | 0.753 |
    Ce-Ut | 33 (21.7) | 14 (23.7) |  |
    Mt-Ae | 119 (78.3) | 45 (76.3) |  |
Macroscopic type | Â | Â | 0.601 |
    0-Is/0-Iia | 12 (7.9) | 6 (10.2) |  |
    0-IIb/0-Iic | 140 (92.1) | 53 (89.8) |  |
Tumor size (mm), mean ± SD | 34.4 ± 17.8 | 46.2 ± 20.3 |  < 0.01 |
Resection area |  |  |  < 0.01 |
    Entire circumference | 19 (12.5) | 28 (47.5) |  |
    Sub-circumference | 133 (87.5) | 31 (52.5) |  |
Muscle layer damage | Â | Â | 0.375 |
    +  | 13 (8.6) | 3 (5.1) |  |
    −  | 139 (91.4) | 56 (94.9) |  |
Prophylactic methods of stenosis | Â | Â | 0.0649 |
    TrA injection only | 70 (46.0) | 19 (32.2) |  |
    TrA injection + oral PSL | 82 (54.0) | 40 (67.8) |  |
Pathological tumor depth | Â | Â | 0.729 |
    pT1a | 134 (88.2) | 53 (89.8) |  |
    pT1b | 18 (11.8) | 6 (10.2) |  |
Additional CRT after ESD | Â | Â | 0.225 |
    +  | 22 (14.5) | 5 (8.5) |  |
    −  | 130 (85.5) | 54 (91.5) |  |